19:18 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease In vitro and mouse studies identified a triazoloquinolone-based CLK-1 inhibitor that could help treat acute liver injury (ALI). In silico screening of small compound libraries, chemical synthesis of analogs of the screening hit...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Calmodulin; CDC-like kinase 1 (CLK-1); vascular endothelial growth factor receptor 3 (FLT4; VEGFR-3); K(lysine) acetyltransferase 5 (KAT5); acetyl

Infectious disease INDICATION: Chikungunya virus Cell culture and mouse studies identified inhibitors of calmodulin, CLK-1, FLT4, KAT5 and other host factors that could help treat Chikungunya viral infection. Screening of an siRNA library targeting about 17,000 genes...
08:00 , Feb 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Influenza virus; cancer CDC-like kinase 1 (CLK1); CLK4 An in vitro study...
07:00 , May 1, 2006 |  BC Week In Review  |  Clinical News

CHGN111: Phase I/II start

Chronogen will begin this week an open-label Canadian Phase I/II trial in 24 healthy volunteers. Chronogen Inc., Montreal, Quebec   Product: CHGN111   Business: Dermatology   Molecular target: CLK-1   Description: Mitochondrial enzyme CLK-1 inhibitor   Indication: Prevent cutaneous...
08:00 , Nov 25, 2002 |  BC Week In Review  |  Company News

Chronogen, McGill University deal

Chronogen exclusively licensed from the university proteins CLK-1, CLK-2, and ISP-1, in addition to a series of targets for age-dependent diseases like cardiovascular disorders and cancer. The company said the proteins are associated in...